Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eventually develop resistance. New drugs and treatments are necessary for these patients. One attractive approach is to inhibit multiple parallel pathways that drive the growth of these hematologic tumors, possibly prolonging the duration of the response and reducing resistance. Early clinical trials have tested this approach by dosing two drugs in combination in NHL patients. We discovered a single molecule, MDVN1003 (1-(5-amino-2,3-dihydro-1H-inden-2-yl)-3-(8fluoro-3,4-dihydro-2H-benzo[b] [1, 4]oxazin-6-yl)-1H-pyrazolo[3,4d]pyrimidin-4-amine), that inhibits Bruton's tyrosine kinase and phosphatidylinositol-3-kinase d, two proteins regulated by the B cell receptor that drive the growth of many NHLs. In this report, we show that this dual inhibitor prevents the activation of B cells and inhibits the phosphorylation of protein kinase B and extracellular signal-regulated kinase 1/2, two downstream mediators that are important for this process. Additionally, MDVN1003 induces cell death in a B cell lymphoma cell line but not in an irrelevant erythroblast cell line. Importantly, we found that this orally bioavailable dual inhibitor reduced tumor growth in a B cell lymphoma xenograft model more effectively than either ibrutinib or idelalisib. Taken together, these results suggest that dual inhibition of these two key pathways by a single molecule could be a viable approach for treatment of NHL patients.
Introduction
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kinases downstream of the BCR are Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase d (PI3Kd) (Seda and Mraz, 2015) . BTK is a member of the Tec family of tyrosine kinases and is recruited to the cell membrane after the activation of the BCR. Together with Syk, BTK phosphorylates phospholipase C-g2, producing the classic second messengers diacylglycerol and inositol-1,4,5-triphosphate from phosphatidylinositol-4,5bisphosphate. Diacylglycerol activates protein kinase C, and inositol-1,4,5-triphosphate triggers the release of intracellular calcium, resulting in the activation of several downstream signaling molecules, including extracellular signal-regulated kinase 1/2 (ERK 1/2) (Tomlinson et al., 2001) . PI3Kd is also recruited to the cell membrane and activated in response to BCR signaling. PI3K is a heterodimer composed of the p85 regulatory subunit and the p110 catalytic subunit, which in B cells is the d isoform. PI3Kd is involved in recruiting BTK to the cell membrane and phosphorylates and activates several downstream signaling molecules, including protein kinase B (AKT) (Fruman and Rommel, 2014) . The BTK and PI3Kd signaling pathways are not insulated from one another, and there is evidence of cross-talk between them (Puri et al., 2013) . Both BTK and PI3Kd are involved in normal B cell signal propagation but have been identified as being aberrantly activated in many B cell malignancies (Seda and Mraz, 2015) . These proteins are the targets of the approved therapies: ibrutinib, an irreversible BTK inhibitor, and idelalisib, a reversible PI3Kd inhibitor.
Ibrutinib blocks the enzymatic activity of BTK through covalent binding to a conserved cysteine residue (Cys481) in the active site (Honigberg et al., 2010) . Ibrutinib was approved by the Food and Drug Administration for use in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia patients. Idelalisib is a highly selective ATP competitive inhibitor of PI3Kd (Lannutti et al., 2011; Marini et al., 2016) and has been approved for use in CLL, follicular cell NHL, and relapsed small lymphocytic lymphoma patients (Do et al., 2016) .
Although the approval of these targeted therapies by the Food and Drug Administration was a significant advance, it has been reported that about 30% of MCL and CLL patients show primary resistance to ibrutinib (Tucker and Rule, 2015) . Furthermore, a subset of patients who initially respond to and receive prolonged treatment of ibrutinib eventually relapse due to the development of mutations in BTK that prevent the covalent binding of ibrutinib or gain-of-function mutations in phospholipase C-g2 (Byrd et al., 2013; Wang et al., 2013; Smith, 2015) . The resistance to idelalisib is not as well understood. Several reports have suggested that combination dosing of ibrutinib and idelalisib could be advantageous since targeting parallel pathways downstream of the BCR could reduce the risk of signal switching, leading to escape from tumor growth inhibition (Jones and Byrd, 2014; Mathews Griner et al., 2014; Zhang et al., 2014; de Rooij et al., 2015; Koehrer and Burger, 2016) .
In this report, we describe proof-of-concept preclinical studies with tool compound MDVN1003 (1-(5-amino-2,3- [1, 4] oxazin-6-yl)-1H-pyrazolo [3,4-d] pyrimidin-4-amine), a first-in-class dual inhibitor of BTK and PI3Kd kinases . We found that MDVN1003 inhibits B cell activation upon BCR cross-linking ex vivo and in vivo, a phenomenon dependent on BTK and PI3Kd. Additionally, MDVN1003 induces apoptosis and decreases viability of DOHH-2 cells, an NHL cell line. Finally, MDVN1003, an orally bioavailable molecule in mice, rats, and dogs, showed significant antitumor effects in an NHL xenograft model in mice. This effect was similar to that seen with combination dosing of ibrutinib and idelalisib in the same model and greater than each of these drugs dosed as single agents. Our results suggest that a dual inhibitor of BTK and PI3Kd could be an effective treatment strategy for B cell lymphoma patients.
Materials and Methods
Reagents and Tumor Cell Lines. Ibrutinib (CAS 936563-96-1) and idelalisib (CAS 870281-82-6) were purchased from ChemShuttle (Union City, CA). Compounds MDVN1003, MDVN1001 (5-(8-fluoro-3,4-dihydro-2H-benzo[b] [1, 4] oxazin-6-yl)-7-(5-(piperidin-4-yl)-2,3-dihydro-1H-inden-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine), and MDVN1002 (1-(5-amino-2,3- [3,4-d] pyrimidin-4-amine) were synthesized at Integral Bio-Sciences, Pvt. Ltd. (Noida, India). All tumor cell lines were purchased from the American Type Culture Collection (Manassas, VA) and were tested for mycoplasma by polymerase chain reaction. All revived cells were used within 20 passages and cultured for less than 6 months. Ramos and DOHH-2 cells were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum supplemented with penicillin and streptomycin.
Enzymatic Kinase Assays. In vitro kinase activity assays were performed by Reaction Biology Corporation (www.reactionbiology. com) as described on the Web site and as described previously .
Assessment of BCR-Dependent Signaling Levels. Ramos cells were pretreated for 30 minutes with compounds (0.1 or 1 mM final concentration) and then stimulated with a-human IgM (1.3 mg/ml) (#109-006-129; Jackson ImmunoResearch Laboratories, Inc., Westgrove, PA) for 5 minutes. Levels of phosphorylated AKT (pAKT) (#4060; Cell Signaling Technology, Danvers, MA), AKT (#9272; Cell SignalingTechnology), phosphorylated Erk (pErk; T202, Y204) (#4377; Cell Signaling Technology), and ERK (#4396; Cell Signaling Technology) were detected by western blot using the ChemiDoc Imaging System (Bio-Rad, Hercules, CA).
Measuring B Cell Activation by CD69 Expression. Splenocytes (1 Â 10 6 cells/well) were seeded in a 24-well plate and pretreated for 30 minutes with compounds at indicated concentrations and then activated for 4 hours with a-mouse IgD (3 mg/ml) (YULLOMD6-05; Accurate Chemical, Westbury, NY). Cells were stained with a-B220 PE (#553090; BD Biosciences, San Jose, CA), a-CD69 APC (#130-103-947; Miltenyi Biotec, Gladbach, Germany), and with a live/dead fixable aqua dead cell kit (#L34957; ThermoFisher Scientific, Grand Island, NY) and analyzed by flow cytometry using a MACSQuant Analyzer 10 flow cytometer (Miltenyi Biotech, Gladbach, Germany) .
At each concentration of compound tested, the inhibition of B cell activation was calculated as the percentage of live B cells expressing CD69 in the presence of the compound divided by the percentage of live B cells expressing CD69 in the vehicle control. Splenocytes from three individual mice were treated independently per condition tested. The IC 50 was calculated from the average of the three independent experiments, and curve fitting was done by nonlinear regression using GraphPad Prism (GraphPad Software, La Jolla, CA).
Viability Assay. DOHH-2 or HEL 92.1.7 cells were seeded in a 96-well white plate overnight at a density of 5000 cells/well. Cells were treated with compounds at the indicated concentrations for 72 hours. Cell viability was measured using a Cell Titer-glo kit (Promega, Madison, WI) as described by the manufacturer. The IC 50 was calculated from the curve fitted to the data points by nonlinear regression using GraphPad Prism.
Dual Inhibition of BTK and PI3Kd to Treat B Cell Cancers
Apoptosis Assay. DOHH-2 cells were seeded in a 24-well plate at 0.5 Â 10 6 cells/well. Cells were then treated with compounds at 1 mM for 4 hours, and apoptosis was measured by flow cytometry (MACS-Quant Analyzer 10) using an Annexin V FITC apoptosis detection kit (#556547; BD Biosciences).
Pharmacokinetic Analysis. All animal studies were done as per protocols approved by the Institutional Animal Care and Use Committee at Medivation or its subsidiaries. See Supplemental Material for experimental details of mouse, rat, and dog pharmacokinetic (PK) studies.
Measuring B Cell Activation by CD69 Expression In Vivo. BALB/c mice were orally dosed with compounds (n 5 3 per group) at indicated concentrations for 30 minutes, and then mice were injected intravenously in the tail vein with 100 mg of a-IgD (YULLOMD6-05; Accurate Chemical, Westbury, NY) for 5 hours. Splenocytes were isolated and stained and analyzed as described earlier. The percentage of live B cells that express CD69 from mice treated with a-IgD and compound was normalized to the percentage of live B cells that express CD69 from mice treated with a-IgD alone.
Mouse Xenograft Model. All animal studies were done as per protocols approved by the Institutional Animal Care and Use Committee at Medivation or its subsidiaries.
DOHH-2 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and were passaged twice weekly. While in the exponential growth phase, 5 million DOHH-2 cells in 0.1 ml of phosphate-buffered saline (1:1 ratio with matrigel) were inoculated into the right flanks of 6-to 7-week-old female CB17/SCID mice (denoted as day 0). When the average tumor volume reached 118 mm 3 , mice were randomly grouped into eight groups (n 5 10 per group). Tumor volume and body weight were measured twice a week. The experiment was terminated when the average tumor volume of the vehicle group reached .2000 mm 3 , and plasma and tumor samples were collected from each mouse (n 5 3 mice per group were sacrificed 5 minutes before the final dose, n 5 3 mice per group were sacrificed 30 minutes post final dose, and n 5 4 mice per group were sacrificed 6 hours post final dose). Statistical analysis (Kruskal-Wallis corrected for multiple comparisons) was done on the tumor volumes of the groups over time.
Results
As described , we aimed to discover reversible dual BTK and PI3Kd inhibitors based on the similarities between a reversible BTK inhibitor, PCI-29732 (1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine) (Pan et al., 2007; Marcotte et al., 2010) , and a PI3Kd/g dual inhibitor, SW13 (2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-(otolyl)quinazolin-4(3H)-one) (Berndt et al., 2010) . We identified three compounds ( Fig. 1) , two of which are more potent against one of the two receptors and one compound that is a more potent dual inhibitor (Table 1 ; synthesis in Supplemental Methods). On the one hand, MDVN1001 is a potent BTK inhibitor (IC 50 0.9 nM) and a relatively weak PI3Kd inhibitor (IC 50 149 nM). On the other hand, MDVN1002 strongly inhibited PI3Kd (IC 50 25.9 nM) more than it did BTK (IC 50 695 nM). However, the dual inhibitor, MDVN1003, potently inhibited both kinases (BTK with an IC 50 of 32.3 nM, and PI3Kd with an IC 50 of 16.9 nM). As expected, the control compounds, idelalisib and ibrutinib, inhibited one kinase more strongly than the other. Idelalisib, an ATP competitive, reversible inhibitor of PI3Kd, inhibited PI3Kd with an IC 50 of 1.2 nM, whereas it did not measurably inhibit BTK at any concentration tested. Ibrutinib, an irreversible inhibitor of BTK, potently inhibited BTK (IC 50 0.142 nM) and weakly inhibited PI3Kd (IC 50 640 nM).
To investigate the effects of these molecules on signaling through the BCR pathway, phosphorylation of ERK 1/2 and AKT was measured in the Ramos Burkitt's B cell lymphoma cell line. Ramos cells were pretreated with vehicle or 0.1 mM idelalisib, ibrutinib, MDVN1001, MDVN1002, MDVN1003, or an equimolar cotreatment of idelalisib and ibrutinib (subsequently referred to as "combo"). Cells were treated with a-human IgM for 5 minutes to cross-link and activate the BCR. Levels of phosphorylated ERK 1/2 and AKT were detected by western blot (Fig. 2) . Treatment with a-human IgM increased the levels of phosphorylated AKT and ERK 1/2 as compared with the vehicle alone, indicating the BCR signaling pathway was activated (Fig. 2, lanes 1 and 2) . Ibrutinib and idelalisib treatments significantly reduced the levels of pERK 1/2 and pAKT. Neither MDVN1001 nor MDVN1002 significantly affected levels of pAKT or pERK 1/2 when tested at 0.1 mM. However, these compounds did inhibit the phosphorylation of AKT and ERK 1/2 at higher concentrations (Supplemental Fig. 1 ). Combination treatment of idelalisib and ibrutinib potently inhibited levels of both pAKT and pERK 1/2 (Fig. 2) . The MDVN1001 and MDVN1002 combination treatment (combo MDVN) also inhibited the phosphorylation of AKT and ERK1/2, although not as potently as the combination treatment of the two approved inhibitors (Supplemental Fig. 1 ). Treatment with the dual BTK/PI3Kd inhibitor compound MDVN1003 inhibited the phosphorylation of AKT and ERK 1/2 at both the low concentration (0.1 mM) and the high concentration (1 mM) and did so more potently than the combination of MDVN1001 and MDVN1002 ( Fig. 2 ; Supplemental Fig. 1 ). Taken together, these data show that MDVN1003 is a more potent inhibitor of BCR signaling than either MDVN1001 or MDVN1002 dosed individually or in combination and suggest that the dual inhibition of BTK and PI3Kd may have a synergistic effect on downstream signaling molecules.
We wanted to further investigate the potential synergy of inhibiting both BTK and PI3Kd in B cell lymphomas using ibrutinib, idelalisib, and MDVN1003 as tool compounds. These compounds provided us with the necessary tools to study treatment with monotherapies and dual inhibition. MDVN1003 is more potent than either MDVN1001 or MDVN1002 (or the combination of both) in the cell-based assay and allowed us to study dual inhibition in a single molecule.
To understand the selectivity profile of MDVN1003 and how it compares to those of ibrutinib and idelalisib, we tested these compounds in a kinase panel at 1 mM. Idelalisib is a highly selective PI3Kd inhibitor and inhibited four other kinases (out of 374 tested) greater than 50%. Ibrutinib inhibited 34 kinases (out of 374 tested) more than 50% ( Fig. 3 ). MDVN1003 behaved similarly to ibrutinib in the kinase panel and inhibited 50 kinases (out of 402 tested) at greater than 50%, with a preference for tyrosine kinases (Fig. 3 ). Among the kinases most potently inhibited by MDVN1003 were BTK, PI3Kd, and the related Tec-and PI3K-family kinases ( Fig. 3 ; Table 2 ).
We next investigated the effects of MDVN1003 on the activation of primary B cells ex vivo. Mouse splenocytes were pretreated with ibrutinib, idelalisib, combo, or MDVN1003 for 30 minutes. Cells were treated with a-IgD for 4 hours to activate B cells. Anti-IgD cross-links the surface immunoglobulin and activates the B cell, which upregulates the early B cell activation marker CD69 (Sancho et al., 2005) . Activated B cells were detected by flow cytometry as B221CD691 in a gate of live cells. The inhibition of B cell activation was measured by the percentage of live B cells that expressed CD69 on the cell surface in treated samples as compared with the a-IgD control. Ibrutinib and idelalisib potently inhibited B cell activation, with IC 50 values of 6.9 and 5.4 nM, respectively ( Fig. 4A ; Table 3 ). Idelalisib, but not ibrutinib, produced full inhibition of B cell activation. The combo treatment of both compounds showed a modest additive effect with an IC 50 of 1.1 nM ( Fig. 4A ; Table 3 ) and produced full inhibition of B cell activation. MDVN1003 inhibited B cell activation with an IC 50 of 25.2 nM ( Fig. 4A ; Table 3 ). Although less potent, MDVN1003 was equally as efficacious as idelalisib and the combo treatment and fully inhibited B cell activation.
Signaling through the BCR is often a driver of tumor growth in B cell malignancies (Buchner and Muschen, 2014) , and it has been reported that both ibrutinib and idelalisib reduce cell viability and induce apoptosis in NHL B cell lines (Honigberg et al., 2007; Lannutti et al., 2011; Qu et al., 2015) . To determine whether MDVN1003 behaved similarly to the approved drugs, we measured the effect of MDVN1003 on the viability of DOHH-2 cells, a non-Hodgkin's B cell lymphoma line that expresses BTK and PI3Kd. After 72 hours of treatment, MDVN1003 effectively killed DOHH-2 cells with an IC 50 of 1.34 mM, whereas the IC 50 values for ibrutinib and idelalisib were 0.023 and 0.86 mM, respectively ( Fig. 4B ; Table 3 ). The IC 50 for the combo treatment was 0.0084 mM, suggesting an additive effect on cell viability in inhibiting both BTK and PI3Kd. The cytotoxicity induced by these compounds was determined to be apoptosis, as indicated by the significant population of Annexin V1 propidium iodide2 cells in treatment groups as compared with the vehicle control (P , 0.0001, one-way analysis of variance) ( Fig. 4C ). Combination treatment of MDVN1001, the BTK inhibitor, and MDVN1002, the PI3Kd inhibitor, also showed an additive effect on cell viability of DOHH-2 cells with an IC 50 of 0.87 mM, as compared with IC 50 values of 1.47 mM with MDVN1001 alone and 2.75 mM with MDVN1002 alone (Supplemental Fig. 2) . Although a modest effect, these data suggest a benefit of dual inhibition of BTK and PI3Kd.
To understand if the cytotoxicity of these compounds was dependent on inhibition of BTK and PI3Kd, we tested the effects of the compounds on viability of HEL 92.1.7 erythroblast-like cells that do not express these kinases. The IC 50 values of ibrutinib, idelalisib, combo, and MDVN1003 were all greater than 10 mM (Table 3 ), suggesting that these compounds are preferentially cytotoxic in cells that express BTK and PI3Kd. Ramos cells were pretreated for 30 minutes with either dimethylsulfoxide (lanes labeled vehicle and -) or the indicated compounds... the indicated compounds (0.1 mM). All samples, except for the vehicle control, were treated with a-IgM (1.3 mg/ml) for 5 minutes to activate BCR signaling. Levels of pAKT and pERK 1/2 and the corresponding total proteins were determined by western blot. Combo is equimolar (0.1 mM) treatment of ibrutinib and idelalisib. To study the pharmacology of MDVN1003 in vivo, we investigated the PK properties of this molecule across species. The PK profiles of MDVN1003 in mice, rats, and dogs after a single oral dose are shown in Fig. 5 . The noncompartmental analysis PK parameters of MDVN1003 in mice, rats, and dogs are summarized in Table 4 . Following oral administration in mice, MDVN1003 showed rapid absorption, with a time of maximum concentration in plasma (t max ) of 0.25 hours, and then declined with a biexponential decay and an elimination half-life (t 1/2 ) of 1.3 hours (Fig. 5 ). The absolute oral bioavailability (F) was acceptable at 40%. Following intravenous administration in mice, MDVN1003 showed low systemic clearance (0.6 l/h/kg) that was 13% of hepatic blood flow in the mouse [Q H 5 4.7 l/h/kg (Davies and Morris, 1993) ] and a moderate volume of distribution (V d 5 3.4 l/kg), as shown in Table 4 . Following oral administration in rats, MDVN1003 showed rapid absorption with a t max of 0.25 hours, and then declined with a biexponential decay and a t 1/2 of 1.2 hours (Fig.  5 ). The absolute oral bioavailability (F) was an acceptable 31%. Following intravenous administration in rats, MDVN1003
showed high systemic clearance (4.94 l/h/kg) that was 150% of hepatic blood flow in the rat [Q H 5 3.31 l/h/kg (Davies and Morris, 1993) ] and a moderate volume of distribution (V d 5 2.0 l/kg), as shown in Table 4 . Following oral administration in dog, MDVN1003 showed rapid absorption, with a t max of 0.42 hours, and then declined with a biexponential decay and a t 1/2 of 1.5 hours (Fig. 5) . The absolute oral bioavailability (F) was a moderately high 62%. Following intravenous administration in dog, MDVN1003 showed moderate systemic clearance (1.23 l/h/kg) that was 66% of hepatic blood flow in the dog [Q H 5 1.85 l/h/kg (Davies and Morris, 1993) ] and a moderate volume of distribution (V d 5 1.0 l/kg), as shown in Table 4 .
Given the low clearance and acceptable oral bioavailability of MDVN1003 in mice, we aimed to show pharmacological Fig. 4 . MDVN1003 inhibits B cell activation in mouse splenocytes and induces apoptosis in DOHH-2 B cell lymphoma cells. (A) Splenocytes were pretreated with the indicated compounds at different concentrations for 30 minutes and then treated with a-IgD (3 mg/ml) for 4 hours to activate BCR signaling. Activated B cells were identified by flow cytometry as the B220+CD69+ cells in a live gate. To calculate the effect of each compound on the inhibition of B cell activation, the percentage of B220+CD69+ cells in each condition was normalized to the a-IgD vehicle control. The IC 50 was calculated from the curve fitted to the data points by nonlinear regression using GraphPad Prism. (B) DOHH-2 cells were treated with compounds at the indicated concentrations for 72 hours. Cell viability was measured as described in the Materials and Methods. The IC 50 was calculated from the curve fitted to the data points by nonlinear regression using GraphPad Prism. (C) DOHH-2 cells were treated with compounds at 1 mM for 4 hours, and apoptosis was measured by flow cytometry using an Annexin V FITC apoptosis detection kit. Apoptotic cells were determined as Annexin V+ propidium iodide (PI)2 by flow cytometry. Dot plots from a representative experiment are shown in the top panels, and a summary of the percentages of apoptotic cells from four independent experiments is plotted in the bottom panel (mean 6 standard deviation, ****P , 0.0001, one-way analysis of variance). PI-A, propidium idodide area.
Dual Inhibition of BTK and PI3Kd to Treat B Cell Cancers efficacy, as proof of concept, in two in vivo mouse models: a model of B cell activation and a xenograft model of non-Hodgkin's B cell lymphoma. To test the effect of the compounds on B cell activation in vivo, BALB/c mice were prophylactically dosed with different oral doses of compound for 30 minutes prior to being challenged with an a-IgD antibody administered intravenously via tail vein to activate BCR signaling for up to 5 hours (Fig. 6A) . After the treatment, splenocytes were isolated, and activated B cells were detected by flow cytometry as B2201CD691 in a gate of live cells. With no a-IgD treatment, between 3 and 5% of B cells were active basally (CD691) in spleens (data not shown). In mice treated orally with vehicle and intravenously with a-IgD, around 30% of B cells were CD691 (data not shown). This value was set to 100% activation, and the percentages of CD691 B cells in the drug-treated mice were normalized to the percentage of CD691 B cells in the a-IgD-treated control group. Ibrutinib effectively inhibited (.50%) B cell activation at all doses tested (10, 50, and 100 mg/kg), whereas idelalisib only inhibited B cell activation by 50% at 10 mg/kg ( Fig. 6B ) but was effective at higher doses. MDVN1003 did not inhibit B cell activation at 10 mg/kg but inhibited activation by 75% at 50 and 100 mg/kg (Fig. 6B) . The lack of a dose response at 50 and 100 mg/kg of MDVN1003 may suggest that absorption of this compound is already saturated at 50 mg/kg.
Given that MDVN1003 induced cell death in DOHH-2 cells and inhibited B cell activation in vivo, we tested whether this compound was able to inhibit tumor growth in vivo in a DOHH-2 B cell lymphoma xenograft model. Six-to 7-week-old CB17/SCID mice were inoculated in the right flank with 5 Â 10 6 DOHH-2 cells. Mice were grouped (n 5 10/group) and dosing began when tumors reached an average of 100 mm 3 . Dosing was terminated when the average tumor volume of the vehicle group reached 2000 mm 3 . Mice were placed into one of eight groups and dosed with vehicle, two doses of ibrutinib (15 or 30 mg/kg), two doses of idelalisib (25 or 50 mg/kg), two combinations of ibrutinib and idelalisib (15 mg/kg ibrutinib/ 25 mg/kg idelalisib or 30 mg/kg ibrutinib/50 mg/kg idelalisib), or one dose level of MDVN1003 (100 mg/kg). Ibrutinib was dosed once daily due to its irreversible binding, and idelalisib and MDVN1003 were both dosed twice daily. Mice were monitored for body weight and tumor volume over the 21 days of dosing. The body weight of the mice was unaffected by the treatments (Fig. 6C) . Tumor growth was slowed by combination treatment of ibrutinib and idelalisib and by treatment with MDVN1003 (Fig. 6, D and E) . On the final day of dosing (day 31 postinoculation), ibrutinib at either 15 or 30 mg/kg reduced average tumor volume by 15.7 and 24.7%, respectively, and idelalisib at 25 or 50 mg/kg reduced average tumor volume by 6.6 and 14.2%, respectively, as compared with the vehicle control group (not statistically significant). When dosed in combination, the average tumor volume of the ibrutinib (15 mg/kg) and idelalisib (25 mg/kg) low combo group was reduced by 38.1% as compared with the vehicle group, whereas tumors in the ibrutinib (30 mg/kg) and idelalisib (50 mg/kg) high combo group were reduced by 57.9% on average as compared with the vehicle control group (P , 0.001, Kruskal-Wallis corrected for multiple comparisons). Treatment with MDVN1003 reduced tumor growth by 45.2% (P , 0.01, Kruskal-Wallis corrected for multiple comparisons).
Discussion
The potential advantage of dual inhibition of BTK and PI3Kd for treatment of NHL lies in the possibility of treating refractory patients or overcoming developed resistance to either BTK or PI3Kd single inhibitors due to the synergistic or additive effects of blocking two BCR pathway targets. Codosing BTK and PI3Kd single inhibitors is one approach to gaining the advantage of dual inhibition. Preclinical evidence supports the notion that inhibiting these two pathways could result in synergistic or additive effects. Combination treatments of JeKo1 cells, an MCL cell line, with ibrutinib and idelalisib resulted in decreased adhesion to fibronectin, a BCR-dependent process, as compared with cells treated with each drug individually (de Rooij et al., 2015) . The authors found a strong synergistic effect with the dual treatment. In another example, combination treatment of BCWM.1 Waldenström's macroglobulinemia cells with both ibrutinib and the highly selective second-generation PI3Kd inhibitor TGR-1202 (Davids et al., 2016) .
In this report, we corroborate the findings that cotreatment of B cells with ibrutinib and idelalisib results in effects superior to those seen with either drug dosed individually. 5 . MDVN1003 concentration-time profile following an oral dose in mouse, rat, and dog. Mice, rats, and dogs were treated orally (PO) or intravenously (data not plotted), and drug concentrations in plasma were monitored over time by liquid chromatography with tandem mass spectrometry analysis. The PK parameters are shown in Table 4 .
The phosphorylation of downstream signaling molecules AKT and ERK 1/2 was significantly dampened in cells treated with both drugs as compared with each drug individually (Fig. 3) . Similarly, in the xenograft model, codosing the two inhibitors more effectively reduced the tumor burden than dosing each compound separately (Fig. 6) . These data support the hypothesis that targeting two BCR-controlled pathways could be more efficacious than treatment with a monotherapy.
Preclinical data suggesting the potential synergism of inhibiting both BTK and PI3Kd have spurred clinical trials of combination treatments. TG Therapeutics has several ongoing clinical studies with TGR-1202 and ibrutinib for B cell malignancies, including relapsed or refractory CLL and MCL. From their phase I/Ib study, TG Therapeutics has reported interim results showing an overall response rate of 82% in CLL and 60% in MCL, but has yet to show a reduction in the rate of resistance (Davids et al., 2016) .
Although combination treatment of two separate BTK and PI3Kd inhibitors does provide the advantage of being able to independently control the dose of each inhibitor, we tested the hypothesis that a dual inhibitor in a single molecule could be a potential therapeutic approach for NHL. Having the dual inhibition activity built into a single molecule could ease the toxicology profile since there would be a single set of off-target effects. The cost of treatment of patients may also be lower with a single molecule due to lower manufacturing and formulation costs (Shanafelt et al., 2015) . We have previously described our discovery of dual BTK and PI3Kd inhibitors , and here, we report that one of these dual inhibitors does exhibit properties similar to combination dosing of ibrutinib and idelalisib, albeit not as potent or selective.
MDVN1003, although a dual inhibitor of BTK and PI3Kd, is not as potent an inhibitor as idelalisib and ibrutinib are against their primary targets as measured in in vitro enzymatic assays ( Table 1 ). Despite the difference in potencies, MDVN1003 inhibits the in vitro phosphorylation of AKT and ERK 1/2 as well as either ibrutinib or idelalisib. MDVN1001 and MDVN1002 are potent single inhibitors of BTK and PI3Kd, respectively, but these compounds only inhibited the phosphorylation of AKT or ERK 1/2 at the higher concentration of 1 mM. This could be due to the lower potency of MDVN1002 against PI3Kd molecules or possibly due to a difference in the cell permeability of MDVN1001 and MDVN1002. Similar to the combo treatment with ibrutinib and idelalisib, combination treatment with MDVN1001 and MDVN1002 showed an additive effect on the inhibition of the phosphorylation of AKT and ERK1/2 upon BCR activation and on cell viability of DOHH-2 cells. Taken together, the data suggest a synergistic effect of dual inhibition of BTK and PI3Kd and by MDVN1003. This is further supported by the superior efficacy of MDVN1003 in the xenograft model as compared with either ibrutinib or idelalisib dosed individually. The difference in potency of MDVN1003 against BTK and PI3Kd could explain why treatment with this compound is not as effective as combo dosing of ibrutinib and idelalisib in vitro or in vivo (Figs. 4 and 6) . Further investigation of the structure-activity relationships of these compounds would be required to identify more potent dual BTK and PI3Kd inhibitors with good oral bioavailability that could be tested for better efficacy in vivo.
Another possibility for the superior performance of MDVN1003 compared with monotherapy in the tumor xenograft model is that the antitumor effect could be unrelated to the inhibition of BTK or PI3Kd. MDVN1003 inhibits many kinases at 1 mM (Fig. 3) , so it is possible that the antitumor effect is not due to synergy of dual inhibition but instead due to the inhibition of another kinase that is required for the growth of DOHH-2 cells. Treatment with MDVN1001, MDV1002, or the combo treatment with these molecules was similarly as potent as MDVN1003 in the cell viability assay, which raises the possibility that the effect on cell viability by these three molecules may not be completely driven by the inhibition of BTK and PI3Kd. However, MDVN1003 is not generally cytotoxic. This molecule, along with ibrutinib and idelalisib, did not induce cell death in HEL 92.1.7 erythroblasts (Fig. 4C) . These cells do not express BTK or PI3Kd, and any other kinase inhibited by MDVN1003 was not sufficient to induce cytotoxicity. Further optimization of the tool compound MDVN1003 is necessary to improve the selectivity profile and fully rule out off-target effects.
In practice, ibrutinib is extremely effective, and the 24-month progression-free survival in the phase I and phase II studies of ibrutinib in CLL was greater than 80% (Tucker and Rule, 2015) . However, 30% of patients are initially refractory to ibrutinib (Tucker and Rule, 2015) , and even more become resistant after long-term dosing (Byrd et al., 2013; Wang et al., 2013; Smith, 2015) , so reducing the rate of resistance or increasing the duration of response could be important for treating patients with B cell malignancies. A potential advantage of combination therapy of BTK and PI3Kd inhibitors may be to reduce the rate of acquired resistance to either BTK or PI3Kd inhibition and potential efficacy in patients initially resistant to treatment of either a BTK or a PI3Kd inhibitor. However, the preclinical data reported here and elsewhere (Jones and Byrd, 2014; Mathews Griner et al., Zhang et al., 2014; de Rooij et al., 2015; Koehrer and Burger, 2016) do not directly test whether dual inhibition or codosing is efficacious in the case of resistance. To date, no preclinical or clinical studies have looked at the effects of cotreatment with BTK and PI3Kd inhibitors on the rates of resistance. In fact, there is a dearth of reagents with which to investigate these questions and a lack of knowledge around adaptive resistance to PI3Kd inhibition.
In summary, our results show that dual inhibition of BTK and PI3Kd by treatment with a single dual inhibitor could potentially improve the outcomes of NHL patients and may prevent resistance or extend the duration of response. Although MDVN1003 proved useful as an initial tool compound, further medicinal chemistry efforts are required to improve potency to achieve cytotoxic and tumor inhibitory effects that match the combination treatment with ibrutinib Mice in all groups except the vehicle control were then dosed intravenously with a-IgD for 5 hours. Splenocytes were isolated and stained with a live/dead marker, aB220, and aCD69 antibodies. Activated B cells were determined as B220+CD69+ in a live gate by flow cytometry. Percentage of activated B cells post compound treatment was normalized to the percentage of active B cells in the a-IgD control (-in graph). (C-E) Compounds were tested in a mouse xenograft model of NHL. Ibrutinib was dosed at 15 mg/kg (light blue) or 30 mg/kg (dark blue); idelalisib was dosed at 25 mg/kg (pink) or 50 mg/kg (red); combo low dosing group was 15 mg/kg ibrutinib and 25 mg/kg idelalisib (ibrutinib/idelalisib low, light green); combo high dosing group was 30 mg/ kg ibrutinib and 50 mg/kg idelalisib (ibrutinib/idelalisib high, dark green); MDVN1003 was dosed at 100 mg/kg. Ibrutinib was dosed orally once daily, and the other two compounds were dosed orally twice daily. (C) Average body weight of mice in each dosing group (mean 6 standard deviation of n = 10 mice per group). (D) Average tumor volume of mice in each dosing group (mean 6 standard deviation, ***P , 0.001, Kruskal-Wallis). (E) The tumor volume of each mouse in the dosing groups on the final day of dosing (day 31 post inoculation). The black line is the average tumor volume of each group, and the colored lines are the standard deviations (***P , 0.001, **P , 0.01, Kruskal-Wallis corrected for multiple comparisons). Cpds, Compounds; HPbCD, hydroxypropyl beta-Cyclodextrin; mpk, mg/kg. and idelalisib. Additional investigation is required to better understand the mechanisms by which resistance to ibrutinib and idelalisib occurs and generate reagents to better elucidate preclinical efficacy. The results presented here provide a proof of concept that a dual inhibitor of BTK and PI3Kd in a single molecule can be developed and could be used as a viable approach for the treatment of B cell malignancies.
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SUPPLEMENTARY INFORMATION
Literature Preparations
The following compounds were prepared by literature methods: Step 
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Preparation of tert-butyl 4-(2-((methylsulfonyl)oxy)-2,3-dihydro-1H-inden-5-yl)piperidine-1carboxylate (IV)
Step 3. To a solution of III (900 mg, 2.84 mmol) in CH 2 Cl 2 (30 mL) was added Et 3 N (1.43 g, 14.2 mmol, 5 eq). The mixture was cooled to 0 °C and methanesulfonyl chloride (638 mg, 5.68 mmol, 2 eq) was slowly added dropwise. The mixture was warmed to room temperature and allowed to stir for 2 h. Upon completion the reaction mixture was extracted with EtOAc (200 mL × 3). The combined organic layers were washed with water (100 mL × 3) followed by brine (30 mL × 2). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to afford IV (1.1 g, 98%) which was used without further purification. JPET #238022 S10
Preparation of tert-butyl 4-(2-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,3-dihydro-1Hinden-5-yl)piperidine-1-carboxylate (VI)
Step 4. Cs 2 CO 3 (1 g, 3.08 mmol, 2 eq) was added to a suspension of V (400 mg, 1.54 mmol) in DMF (10 mL). The reaction mixture was allowed to stir for 45 min at room temperature. Intermediate IV (1.1 g, 2.77 mmol, 1.8 eq) and tetrabutylammonium iodide (104 mg, 0.31 mmol, 0.2 eq) were then added. The mixture was then heated to 95 °C and allowed to stir for 3 h. Upon completion, the mixture was allowed to cool and water (50 mL) was added. The resulting precipitate was collected by vacuum filtration. The filter cake was carefully washed with cold water (40 mL × 2) followed by cold n-pentane (40 mL × 3).
The solids were dried under reduced pressure to afford VI (350 mg, 41%) which was used without further purification. JPET #238022
Analytical data
LC-MS
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Step 5. A reaction vessel was charged with VI (350 mg, 0.625 mmol) and DMF (5 mL). To this was added VII (261 mg, 0.938 mmol, 1.5 eq), Pd(PPh 3 ) 4 (58 mg, 0.05 mmol, 0.08 eq) and Na 2 CO 3 (199 mg, 1.88 mmol, 3 eq) as a solution in water (5 mL). The reaction mixture was heated to 90 °C with stirring and allowed to progress for 3 h. Upon completion, the reaction was quenched with ice cold water (30 mL). The resulting precipitate was collected by vacuum filtration. The filter cake was washed with cold water (40 mL × 3) and cold n-pentane (30 mL × 3). The solids were dried under reduced pressure to afford a crude product which was purified by reversed-phase SiO 2 chromatography (55% CH 3 CN in 10 mM NH 4 OAc). The enantiomers were then separated by chiral preparative HPLC to afford tert-butyl 4-
(2-(4-amino-3-(8-fluoro-3,4-dihydro-2H-benzo [b] [1, 4] oxazin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,3-dihydro-1H-inden-5-yl)piperidine-1-carboxylate (12 mg, 3%) as a single enantiomer.
Analytical data
LC-MS 586 [M+H] +
Step 6. To a reaction vessel containing tert-butyl 4-(2-(4-amino-3-(8-fluoro-3,4-dihydro-2Hbenzo[b] [1, 4] oxazin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,3-dihydro-1H-inden-5-yl)piperidine-1carboxylate (12 mg, 0.02 mmol) was added ethanolic HCl (4 mL) and the resulting mixture was allowed to stir overnight at room temperature. Upon completion, the reaction mixture was concentrated and lyophilized to afford MDVN1001 as a single enantiomer and hydrochloride salt (6 mg, 57%). Step 1. Cs 2 CO 3 (3.49 g, 10.7 mmol, 2 eq) was added to a stirred suspension of V (1.4 g, 5.36 mmol) in DMF (15 mL) at room temperature. The reaction mixture was allowed to stir for 45 min at room temperature. Intermediate VIII (1.82 g, 8.04 mmol, 1.5 eq) and tetrabutylammonium iodide (396 mg, 0.107 mmol, 0.02 eq) were then added. The mixture was then heated to 75 °C and allowed to stir for 90 min. Upon completion, the mixture was allowed to cool and water (30 mL) was added. The resulting precipitate was collected by vacuum filtration. The filter cake was triturated with hexane (10 mL × 2).
Analytical data
LC-MS
The solids were dried under reduced pressure to afford IX (1.7 g, 81%) which was used without further purification. Step 2. A reaction vessel was charged with IX (200 mg, 0.51 mmol) and DMF (3 mL). To this was added X (152 mg, 0.77 mmol, 1.5 eq), Pd(PPh 3 ) 4 (41 mg, 0.036 mmol, 0.07 eq) and Na 2 CO 3 (162 mg, 1.53 mmol, 3 eq) as a solution in water (3 mL). The reaction mixture was heated to 85 °C with stirring and allowed to progress overnight. Upon completion, the reaction was quenched with ice cold water (50 mL). The resulting precipitate was collected by vacuum filtration. The filter cake was washed with cold water (30 mL × 2) and cold n-pentane (40 mL × 2). The solids were dried under reduced pressure to afford a crude product which was purified by reversed-phase SiO 2 chromatography (55-60% CH 3 CN in 10 mM NH 4 OAc) to afford MDVN1002 as a single enantiomer (90 mg, 42%). Step 1. To the stirred solution of XI (50 g, 0.282 mol) in MeOH (2 L) was added NaBH 4 (21.5 g, 0.565 mol, 2 eq) at 0 °C portion wise. The reaction mixture was allowed to stir at 0 °C for 1 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure. The residue was treated with CH 2 Cl 2 , filtered and washed with additional CH 2 Cl 2 . The filtrate was concentrated in vacuo to afford XII (43 g, 85%) as light brown solid. The material was used without further purification.
Analytical data
LC-MS
Analytical data
LC-MS
Analytical data
LC-MS 180 [M+H] +
